PRESS RELEASE published on 06/26/2024 at 07:30, 2 months 23 days ago Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée. Crossject met en perspective le potentiel de ZEPIZURE® à la lumière des études RAMPART et de bioéquivalence. Analyse des avantages de l'injection IM de midazolam dans la prise en charge des crises d'épilepsie Crossject ZEPIZURE RAMPART Étude De Bioéquivalence Injection IM
BRIEF published on 06/18/2024 at 12:35, 3 months 1 day ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Droits De Vote Capital Social AMF Pharmacie Spécialisée Crossject
BRIEF published on 06/18/2024 at 12:35, 3 months 1 day ago Crossject: Information relating to the total number of voting rights and shares making up the share capital Share Capital Voting Rights AMF Crossject Specialized Pharmacy
PRESS RELEASE published on 06/18/2024 at 12:30, 3 months 1 day ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Publication du nombre total de droits de vote et d'actions de CROSSJECT au 31 mai 2024 conformément aux réglementations. Détails sur le capital social Droits De Vote Capital Social AMF Crossject Pharma
BRIEF published on 06/13/2024 at 09:41, 3 months 6 days ago Crossject : Information sur le nombre de droits de vote et d'actions Droits De Vote Capital Social Actions 2024 Crossject
BRIEF published on 06/13/2024 at 09:41, 3 months 6 days ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
PRESS RELEASE published on 06/13/2024 at 09:36, 3 months 6 days ago Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Crossject publie le nombre total de droits de vote et d'actions au 31 mai 2024 conformément aux normes réglementaires Droits De Vote Capital Social Actions Crossject Pharma
BRIEF published on 06/12/2024 at 07:35, 3 months 7 days ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
BRIEF published on 06/12/2024 at 07:35, 3 months 7 days ago Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Crossject ZEPIZURE® Dan Chiche Directeur Médical
PRESS RELEASE published on 06/12/2024 at 07:30, 3 months 7 days ago Crossject appoints Dan Chiche, MD as Chief Medical Officer North America Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025 North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche
Published on 09/19/2024 at 17:30, 43 minutes ago Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Published on 09/19/2024 at 17:00, 1 hour 13 minutes ago Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Published on 09/19/2024 at 15:45, 2 hours 28 minutes ago eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Published on 09/19/2024 at 15:20, 2 hours 53 minutes ago Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Published on 09/19/2024 at 15:01, 3 hours 12 minutes ago ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Published on 09/19/2024 at 17:52, 21 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 21 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:52, 21 minutes ago EQS-Adhoc: SMT Scharf AG: New CEO joins the Managing Board
Published on 09/19/2024 at 17:45, 28 minutes ago AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Published on 09/19/2024 at 17:45, 28 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 28 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 28 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)